139 related articles for article (PubMed ID: 22434494)
1. MR imaging of rectal cancer before and after chemoradiation therapy.
Del Vescovo R; Trodella LE; Sansoni I; Cazzato RL; Battisti S; Giurazza F; Ramella S; Cellini F; Grasso RF; Trodella L; Beomonte Zobel B
Radiol Med; 2012 Oct; 117(7):1125-38. PubMed ID: 22434494
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
[TBL] [Abstract][Full Text] [Related]
3. Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study.
Lambregts DM; Vandecaveye V; Barbaro B; Bakers FC; Lambrecht M; Maas M; Haustermans K; Valentini V; Beets GL; Beets-Tan RG
Ann Surg Oncol; 2011 Aug; 18(8):2224-31. PubMed ID: 21347783
[TBL] [Abstract][Full Text] [Related]
4. T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen.
Martijnse IS; Dudink RL; Kusters M; Vermeer TA; West NP; Nieuwenhuijzen GA; van Lijnschoten I; Martijn H; Creemers GJ; Lemmens VE; van de Velde CJ; Sebag-Montefiore D; Glynne-Jones R; Quirke P; Rutten HJ
Ann Surg Oncol; 2012 Feb; 19(2):392-401. PubMed ID: 21792506
[TBL] [Abstract][Full Text] [Related]
5. Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.
Wong SJ; Winter K; Meropol NJ; Anne PR; Kachnic L; Rashid A; Watson JC; Mitchell E; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1367-75. PubMed ID: 21775070
[TBL] [Abstract][Full Text] [Related]
6. Patterns of practice in the radiation therapy management of rectal cancer: survey of the Interregional Group Piedmont, Valle d'Aosta and Liguria of the "Associazione Italiana di Radioterapia Oncologica (AIRO)".
Di Genesio Pagliuca M; Turri L; Munoz F; Melano A; Bacigalupo A; Franzone P; Sciacero P; Tseroni V; Vitali ML; Delmastro E; Scolaro T; Marziano C; Orsatti M; Tessa M; Rossi A; Ballare A; Moro G; Grasso R; Krengli M
Tumori; 2013; 99(1):61-7. PubMed ID: 23549002
[TBL] [Abstract][Full Text] [Related]
7. Prediction of pathologic staging with magnetic resonance imaging after preoperative chemoradiotherapy in rectal cancer: pooled analysis of KROG 10-01 and 11-02.
Lee JH; Jang HS; Kim JG; Lee MA; Kim DY; Kim TH; Oh JH; Park SC; Kim SY; Baek JY; Park HC; Kim HC; Nam TK; Chie EK; Jung JH; Oh ST
Radiother Oncol; 2014 Oct; 113(1):18-23. PubMed ID: 25245559
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I
Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720
[TBL] [Abstract][Full Text] [Related]
9. Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
Ofner D; Devries AF; Schaberl-Moser R; Greil R; Rabl H; Tschmelitsch J; Zitt M; Kapp KS; Fastner G; Keil F; Eisterer W; Jäger R; Offner F; Gnant M; Thaler J;
Strahlenther Onkol; 2011 Feb; 187(2):100-7. PubMed ID: 21267531
[TBL] [Abstract][Full Text] [Related]
10. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
[TBL] [Abstract][Full Text] [Related]
11. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S
Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322
[TBL] [Abstract][Full Text] [Related]
13. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
[TBL] [Abstract][Full Text] [Related]
14. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
[TBL] [Abstract][Full Text] [Related]
15. [Preoperative chemoradiotherapy for rectal cancer: experience from one centre].
Lescut N; Lepinoy A; Schipman B; Cerda T; Guimas V; Bednarek C; Bosset JF
Cancer Radiother; 2015 Apr; 19(2):98-105. PubMed ID: 25769650
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer.
Gao YH; An X; Sun WJ; Cai J; Cai MY; Kong LH; Lin JZ; Liu GC; Tang JH; Wu XJ; Chen G; Pan ZZ; Ding PR
J Surg Oncol; 2014 Apr; 109(5):478-82. PubMed ID: 24288203
[TBL] [Abstract][Full Text] [Related]
17. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial.
Kennecke H; Berry S; Wong R; Zhou C; Tankel K; Easaw J; Rao S; Post J; Hay J
Eur J Cancer; 2012 Jan; 48(1):37-45. PubMed ID: 21664123
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Chemotherapy with Capecitabine, Oxaliplatin and Bevacizumab Followed by Concomitant Chemoradiation and Surgical Resection in Locally Advanced Rectal Cancer with High Risk of Recurrence - A Phase II Study.
Eisterer W; Piringer G; DE Vries A; Öfner D; Greil R; Tschmelitsch J; Samonigg H; Sölkner L; Gnant M; Thaler J;
Anticancer Res; 2017 May; 37(5):2683-2691. PubMed ID: 28476845
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II-III rectal cancer.
Salazar R; Navarro M; Losa F; Alonso V; Gallén M; Rivera F; Benavides M; Escudero P; González E; Massutí B; Gómez A; Majem M; Aranda E
Clin Transl Oncol; 2012 Aug; 14(8):592-8. PubMed ID: 22855141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]